Bi-modal dose-dependent cardiac response to tetrahydrobiopterin in pressure-overload induced hypertrophy and heart failure.

[1]  D. Harrison,et al.  Uncoupled Cardiac Nitric Oxide Synthase Mediates Diastolic Dysfunction , 2010, Circulation.

[2]  J. Vasquez-Vivar.  Tetrahydrobiopterin, superoxide, and vascular dysfunction. , 2009, Free radical biology & medicine.

[3]  Yang-ming Yang,et al.  eNOS uncoupling and endothelial dysfunction in aged vessels. , 2009, American journal of physiology. Heart and circulatory physiology.

[4]  A. Hale,et al.  Critical Role for Tetrahydrobiopterin Recycling by Dihydrofolate Reductase in Regulation of Endothelial Nitric-oxide Synthase Coupling , 2009, The Journal of Biological Chemistry.

[5]  Jun Zhang,et al.  Sepiapterin reductase regulation of endothelial tetrahydrobiopterin and nitric oxide bioavailability. , 2009, American journal of physiology. Heart and circulatory physiology.

[6]  R. Migrino,et al.  Sepiapterin Decreases Acute Rejection and Apoptosis in Cardiac Transplants Independently of Changes in Nitric Oxide and Inducible Nitric-Oxide Synthase Dimerization , 2009, Journal of Pharmacology and Experimental Therapeutics.

[7]  B. Levy,et al.  Tetrahydrobiopterin Recycling, a Key Determinant of Endothelial Nitric-oxide Synthase-dependent Signaling Pathways in Cultured Vascular Endothelial Cells* , 2009, Journal of Biological Chemistry.

[8]  K. Channon,et al.  L-arginine and tetrahydrobiopterin protects against ischemia/reperfusion-induced endothelial dysfunction in patients with type 2 diabetes mellitus and coronary artery disease. , 2009, Atherosclerosis.

[9]  K. Hirata,et al.  Plasma tetrahydrobiopterin/dihydrobiopterin ratio: a possible marker of endothelial dysfunction. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[10]  Guoyao Wu,et al.  Nitric oxide and vascular insulin resistance , 2009, BioFactors.

[11]  K. Hirata,et al.  Augmentation of Vascular Remodeling by Uncoupled Endothelial Nitric Oxide Synthase in a Mouse Model of Diabetes Mellitus , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[12]  James B. Mitchell,et al.  Reversal of Cardiac Hypertrophy and Fibrosis From Pressure Overload by Tetrahydrobiopterin: Efficacy of Recoupling Nitric Oxide Synthase as a Therapeutic Strategy , 2008, Circulation.

[13]  M. Crabtree,et al.  Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucose-elicited changes in NO vs. superoxide production by eNOS. , 2008, American journal of physiology. Heart and circulatory physiology.

[14]  T. Münzel,et al.  Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. , 2008, Antioxidants & redox signaling.

[15]  A. Quyyumi,et al.  Tetrahydrobiopterin: a novel antihypertensive therapy , 2008, Journal of Human Hypertension.

[16]  N. Alp,et al.  Endothelium-Specific GTP Cyclohydrolase I Overexpression Attenuates Blood Pressure Progression in Salt-Sensitive Low-Renin Hypertension , 2008, Circulation.

[17]  Yi-Hui Sun,et al.  Effects of tetrahydrobiopterin on coronary vascular reactivity in atherosclerotic human coronary arteries. , 2007, Cardiovascular research.

[18]  B. Aronow,et al.  Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart. , 2007, The Journal of clinical investigation.

[19]  F. Ruschitzka,et al.  Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia , 2007, Heart.

[20]  J. Zweier,et al.  Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BH4 , 2007, Proceedings of the National Academy of Sciences.

[21]  D. Kass,et al.  Therapeutic Potential of Tetrahydrobiopterin for Treating Vascular and Cardiac Disease , 2007, Journal of cardiovascular pharmacology.

[22]  A. Chakrapani,et al.  Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study , 2007, The Lancet.

[23]  D. Kass,et al.  Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. , 2005, The Journal of clinical investigation.

[24]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[25]  N. Blau,et al.  Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration. , 2004, Molecular genetics and metabolism.

[26]  K. Rockett,et al.  Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. , 2003, The Journal of clinical investigation.

[27]  C. Vahl,et al.  Endothelial Dysfunction of Coronary Resistance Arteries Is Improved by Tetrahydrobiopterin in Atherosclerosis , 2000, Circulation.

[28]  E. Werner,et al.  Low-temperature optical absorption spectra suggest a redox role for tetrahydrobiopterin in both steps of nitric oxide synthase catalysis. , 2000, Biochemistry.

[29]  H. Drexler,et al.  Vascular extracellular superoxide dismutase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. , 2000, Circulation.

[30]  H. Schmidt,et al.  Allosteric regulation of neuronal nitric oxide synthase by tetrahydrobiopterin and suppression of auto-damaging superoxide. , 2000, The Biochemical journal.

[31]  A. Kashiwagi,et al.  Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2- imbalance in insulin-resistant rat aorta. , 1999, Diabetes.

[32]  C. Nathan,et al.  Reduced biopterin as a cofactor in the generation of nitrogen oxides by murine macrophages. , 1989, The Journal of biological chemistry.

[33]  I. Study.  EPIDEMIOLOGY, CLINICAL FEATURES, AND PROGNOSTIC FACTORS OF PAEDIATRIC HIV INFECTION , 1988, The Lancet.

[34]  R. Cotton,et al.  TETRAHYDROBIOPTERIN TREATMENT OF VARIANT FORM OF PHENYLKETONURIA , 1975, The Lancet.

[35]  R. Cotton,et al.  Letter: Tetrahydrobiopterin treatment of variant form of phenylketonuria. , 1975, Lancet.